GlaxoSmithKline won U.S. approval for a new and improved shingles vaccine, the second of three key products the drugmaker expects approval for in 2017.
Novartis said the U.S. Food and Drug Administration granted breakthrough therapy status to the combination of Tafinlar and Mekinist to treat patients with BRAF V600-positive stage III melanoma following surgery.
An unlisted Swiss biotech company focused on developing “armed antibodies” to fight cancer has raised $200 million in a funding round backed by AstraZeneca and other private backers.
The head of the U.S. Food and Drug Administration said the agency was working with several pharmaceutical and medical device companies in Puerto Rico to prevent shortages of medical products in the United States as it joins a massive effort to help rebuild the island that was ravaged by Hurricane Maria.
A federal prosecutor told jurors that a Massachusetts pharmacist gambled with patients’ lives by making drugs in unsafe ways that led to a deadly 2012 fungal meningitis outbreak, but a defense lawyer said he was not a murderer.
Hospitals nationwide face tough choices when it comes to filling nursing jobs. They are paying billions of dollars collectively to recruit and retain nurses rather than risk patient safety or closing down departments, according to Reuters interviews with more than 20 hospitals, including some of the largest U.S. chains.
Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co.’s loss from a cyber attack in June 2017, according to a forecast by Verisk Analytics Inc.’s Property Claim Services (PCS) unit.
A senior White House aide said U.S. President Donald Trump would demand steps toward repealing Obamacare in any healthcare legislation, comments that cast doubt on the prospects for a short-term bill to shore up insurance markets.
Shares of Imprimis Pharmaceuticals sky-rocketed as much as 91.1 percent after the company said it would offer a cheaper option to Allergan’s dry eye disease medicine Restasis.
Investors are betting on China’s potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West.
U.S. regulators approved a new therapy for a type of lymphoma, which was developed by Gilead Sciences Inc.’s Kite Pharma.
Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. FDA gave the green light to its semaglutide drug.
The prices of injectable cancer drugs – even older medicines around since the 1990s – are increasing at a rate far higher than inflation, researchers report in the Journal of Clinical Oncology.
President Donald Trump Backed away from a bipartisan deal from two U.S. senators to stabilize Obamacare by restoring subsidies to health insurers, one day after signaling his support for the plan.
A U.S. judge’s ruling invalidating Allergan Plc’s patents on its blockbuster $1.5 billion dry-eye medicine Restasis has cast doubt on the company’s novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.
Johnson & Johnson won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company’s talc-based products like Johnson’s Baby Powder.
President Donald Trump’s pick for U.S. drug czar withdrew after it become public that he spearheaded a bill that undercut the government’s power to crack down on opioid makers that were flooding the market with the addictive painkillers.
Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc. in an all-stock deal as the company looks to add heft to its generics business.
Johnson & Johnson reported a higher-than-expected third-quarter 2017 profit and raised its full-year forecast as the company gained from strong sales of its new cancer drugs.
An experimental cancer drug discovered by Hutchison China MediTech demonstrated promising activity in shrinking tumors in lung cancer patients whose disease had worsened following treatment with approved medicines.